Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Arthritis Research & Therapy

Figure 3

From: Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies

Figure 3

Epstein-Barr virus load in peripheral blood mononuclear cells in the longitudinal study. (a) Epstein-Barr virus (EBV) load between week 0 (W0) and week 12 (W12) for all treated patients (n = 42). (b) EBV-specific IFNγ-producing T cells per 106 peripheral blood mononuclear cells between W0 and W12 for all patients receiving anti-TNF drugs (n = 40). PBMCs, peripheral blood mononuclear cells.

Back to article page